Drugs / EG-HZ-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04210752 | Feb → Dec 2020 | herpes zoster | EyeGene Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EG-HZ-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04210752 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular injection” NCT04210752 ↗ |